- ABOUT US
Chairman: Tim Spalding (United Kingdom)
The Arthroscopy Committee has shifted emphasis after the phenomenal success of the book ‘Surgery of the Meniscus’ produced under the leadership of Christophe Hulet in time for the Barcelona congress. With this book now being recognised as the best resource for rationale and treatment for meniscal issues, the committee is geared up to tackle the issues of allografts.
The focus on allografts will cover clinical rationale, advanced science and cost effectiveness. This will be a
Allografts are keenly recognised as a valuable treatment option in orthopaedics, especially in knee surgery. There is, however, lack of clarity in their clinical benefit and more importantly in their availability across Europe. France and Germany, for example have very low availability compared to Scandinavia which has readily available allograft tissue for use. The price is variable and techniques such as osteochondral grafting are expensive at USD 10,000 and not yet available in the UK. Surgeons express frustration at the unequal availability of grafts across Europe and the difficulty in offering the valuable treatment option of allografts to their patients. The ‘European Allograft Initiative’ will look at ligament allografts, osteochondral allografts and meniscus allografts. The areas for the project will include:
We wish to provide the background and detailed information so that surgeons and countries can make appropriate choices. The final goal is a summit meeting in early 2018 bringing together all the relevant stakeholders, and reporting on this in Glasgow 2018.
The primary objective with the Cartilage Committee is to commission a full health technology appraisal on the use and cost-effectiveness of allografts in musculoskeletal treatments. Funding for this will be the challenge.
In summary, this is an ambitious project and will be ongoing work. It may not “succeed” but we will certainly